Frank Winslow, Quad-C Senior Partner, commented, "It's been a pleasure to partner with the PRISM Vision team, and we are thrilled to announce the successful exit to McKesson. Our value creation ...

The latest trading session saw McKesson (MCK) ending at $694.70, denoting a +0.27% adjustment from its last day's close. The stock's performance was ahead of the S&P 500's daily loss of 2.24%.

Prior treatments included topical and oral steroids, systemic antibiotics and antifungals, nystatin powder, A+D Ointment (Schering-Plough Kenilworth, NJ), and three different topical clotrimazole ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and ...

Provenance, or the documented ownership history of your artwork.

With diagnoses at a record high, some experts have begun to question our assumptions about the condition — and how to treat ...

Just think about the savvy investors who held McKesson Corporation (NYSE:MCK) shares for the last five years, while they gained 432%. If that doesn't get you thinking about long term investing ...

McKesson has consistently grown ahead of the broader market in recent years. The stock’s steady earnings should attract safety-minded investors in the current climate. Margins could edge higher ...